Mitsubishi Chemical Group Corporation Q4 FY2025 earnings call

• Overall Strategic Direction

  • The company is in the early execution phase of its KAITEKI Vision 35 long-term vision and new Medium-Term Management Plan 2029, and will accelerate rationalization and actively pursue growth investments in the 2026 March fiscal year.
  • The company will continue to speed up portfolio reform and profit improvement based on the three principles of disciplined business operation: price policy, investment decision-making, and asset optimization, targeting 56.0 billion yen in total profit gains from these measures in the 2026 March period.
  • The company targets to exit/ sell 400 billion yen in non-core revenue between 2024 and 2029, and has already made decisions on 290 billion yen worth of assets, and will continue to implement non-core business sorting and divestment steadily.

• Operational Performance Highlights

  • The 2025 March business environment was broadly stable, with mixed demand across regions and sectors: display-related demand was strong driven by Chinese subsidy policies, semiconductor-related demand recovered gradually driven by generative AI, while automotive and food-related markets were soft in some regions.
  • Aggregate cost reduction reached 60.1 billion yen in 2025 March, exceeding the initial target of 47.0 billion yen.
  • 40% production capacity reduction in the carbon business was completed, contributing to working capital reduction; net interest-bearing debt fell 191.0 billion yen year-over-year, and the net D/E ratio improved to 1.06 from 1.16.
  • A 12.9 billion yen impairment was recorded on US-based Gyrst LLC, which is developing next-generation EUV dry resist precursor products, due to delayed revenue contribution compared to original acquisition projections; the company will strengthen development and streamline operations to improve profitability.
  • Free cash flow for the full year was positive 277.4 billion yen.

• Capital Return

  • The company set a 50.0 billion yen share repurchase program using proceeds from the Tanabe Mitsubishi Pharmaceutical transfer, totaling approximately 510.0 billion yen; all repurchased shares will be cancelled to improve long-term shareholder value. Remaining transfer proceeds will be used for Chemicals business growth investment, debt repayment, or additional new growth investment.
  • The full year 2025 March dividend forecast is 32 yen per share (16 yen year-end), maintained for the 2026 March full year.

For the full year 2025 March period, group total sales revenue was 4.4074 trillion yen, with a 43% increase in core operating profit to 298.4 billion yen compared to the prior year. 1. Specialty Materials: 4% year-over-year revenue increase, 239% year-over-year core operating profit increase, with a 17.7 billion yen year-over-year core profit gain. A one-off 12.9 billion yen impairment loss on JSR Gyrst LLC's assets was recorded in Q4. 2. MMA & Derivatives: 16% year-over-year revenue increase, 29.8 billion yen year-over-year core profit increase, driven by rising MMA monomer market prices. Q4 core profit fell 3.2 billion yen quarter-over-quarter due to weak post-Lunar New Year demand and falling Asian market prices. 3. Basic Materials & Polymers: 12% year-over-year revenue decrease, with a 9.8 billion yen reduction in net loss. The carbon business recorded a 27.9 billion yen net loss, driven by a 11.9 billion yen negative impact from inventory valuation gains/losses. Q4 net loss expanded 2.7 billion yen quarter-over-quarter. 4. Pharma: 5% year-over-year revenue increase, 16% year-over-year core profit increase (9.1 billion yen gain), supported by solid sales of Radicava in North America and growing sales of Mounjaro and Gobic in Japan. Q4 core profit fell 2.2 billion yen quarter-over-quarter due to pre-drug price revision buying delays and end-of-period cost concentration. 5. Industrial Gases: 4% year-over-year revenue increase, 14% year-over-year core profit increase (23.1 billion yen gain), with a 3 billion yen quarter-over-quarter core profit increase in Q4 driven by volume growth and cost cuts in the US. Overall Chemicals business core operating profit improved from a prior-year 11.2 billion yen net loss to a 46.9 billion yen net profit in the current period.

• For the 2026 March full year, the company forecasts total core operating profit of 265.0 billion yen, a 16% increase compared to the 2025 March period (excluding Pharma). Revenue is forecast at 3.74 trillion yen, a 5% decrease year-over-year.
• Core operating profit for the Chemicals business is forecast at 76.0 billion yen, a 78% increase year-over-year, driven by carbon business structural reform, price policies, and cost reduction across all business units.
• Profit attributable to owners of the parent is forecast at 145.0 billion yen, a 222% increase year-over-year, including 94.0 billion yen in profit from discontinued operations related to the Tanabe Mitsubishi Pharmaceutical transfer, which covers Q1 operating profit, transfer gain, and related tax expenses.
• Segment forecasts: 1. Specialty Materials: core profit increase, driven by the elimination of the 12.9 billion yen Gyrst impairment impact, price increases, structural reform, cost cuts, and broad volume growth across sub-segments. 2. MMA & Derivatives: core profit decrease, reflecting current weak market conditions and demand slowdown even with accelerated cost-link formula pricing and cost pass-through. 3. Basic Materials & Polymers: overall core profit decrease, but the carbon business is expected to see a large core profit increase driven by capacity reduction, portfolio optimization, cost cuts, and improved inventory valuation losses. 4. Industrial Gases: continued core profit increase driven by solid demand and productivity improvements.
• The company has already woven in all highly certain downside impacts from current US trade policy and the ongoing MMA market decline into the 2026 March forecast; direct impact from US tariffs is expected to be minor, as around 18% of group revenue is US-focused and most is domestic US transactions. The company expects between 10 billion yen and 20 billion yen in indirect impact, which is already included in the guidance.

• Weak MMA market conditions: Asian MMA market prices continued to decline in Q4 2025 March, falling from 1694 USD/ton in Q3 to 1580 USD/ton in Q4, and demand recovery after the Lunar New Year has been weaker than expected, creating near-term downward pressure on profitability.
• US trade policy indirect impact: While direct impact from US tariff changes is minor, indirect impacts on global supply chains and demand could further pressure MMA and broader chemical market conditions, with continued uncertainty for some product segments such as polyolefin sold to Japanese automakers in Mexico.
• Carbon fiber market competition: The carbon fiber business faces intense competition in pressure vessel applications, leading to a difficult operating environment, and overcapacity in upstream and downstream segments has historically dragged on profitability.
• Inflation cost pressure: Broad-based inflation has pushed up fixed costs including labor costs and R&D expenses across business segments, creating downward pressure on margins.
• Structural reform execution risk: Some cost optimization and non-core exit measures are still in progress, with uncertainty around the timing and magnitude of future profit gains, and remaining customer negotiations for pricing changes add execution uncertainty.

Q: Can management share details on the breakdown of 2026 March profit gains from price policy and asset optimization, and progress on these initiatives? / A: Price policy gains are roughly evenly split between MMA, carbon, and other businesses. MMA and carbon are the largest contributors: for carbon, the company is eliminating unprofitable sales and shifting to cost-linked tolling business models. For asset optimization, the 27.0 billion yen total gain comes from accumulated small-scale measures including plant closures, site consolidation, and capacity optimization across carbon and other businesses, which have been in planning since the 2024 launch of the medium-term plan and are now delivering results. As of now, around 40% of planned carbon business conversions to cost-linked pricing are already finalized, with remaining contracts still under negotiation. Specific details on carbon fiber capacity reduction are not disclosed, but the optimization is already in execution.

Q: How is the 94.0 billion yen profit from discontinued operations (from the Tanabe Mitsubishi Pharmaceutical transfer) structured, and what impact will the transfer proceeds have on the balance sheet? / A: The 94.0 billion yen includes the transfer gain, related tax expenses, Q1 2026 March operating profit from Tanabe Mitsubishi Pharmaceutical (which remains in the group through Q1), and a small amount of inter-group expense transfer, with gains to be recorded across Q1 and Q2. The 50.0 billion yen share repurchase will not cause large changes to the balance sheet. While net interest-bearing debt will decline significantly from the 510.0 billion yen in proceeds, this will be partially offset by ongoing structural reform cash needs and future growth investment, so no large dynamic change to the overall balance sheet structure is expected.

Q: What is the volume growth outlook for key products within the Specialty Materials segment for 2026 March? / A: OPL film demand is currently supported by Chinese subsidies, but growth is expected to stabilize around the end of 2025, so large volume growth is not expected for the full year. For carbon fiber, after capacity optimization, the company will no longer pursue low-margin sales, so total volume is expected to decline slightly this year, but profitability will improve by reallocating high-grade product capacity to higher-margin customers. For semiconductor-related materials, the gradual recovery trend will continue, with solid volume growth expected for products like resists and synthetic quartz powder.

Q: What is the scale of indirect impact from US tariffs, and what is driving the recent decline in inventory? / A: The company expects indirect impact between 10 billion yen and 20 billion yen, which is already fully included in the 265.0 billion yen 2026 core profit guidance. Pre-tariff front-loading demand was minimal overall, with only a small trend seen in film products. The large decline in ending inventory is primarily driven by the downsizing of the carbon business, which reduced raw material and finished goods inventory significantly after 40% capacity reduction.